Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-23 6:22 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 1,839,138 5.100% | -286,459 (-13.48%) | Filing History |
| 2024-03-11 08:19 am Purchase | 2024-03-08 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 6,584,175 18.213% | 377,724 (+6.09%) | Filing History |
| 2024-02-14 8:47 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Venrock Healthcare Capital Partners III L.P. | 3,734,514 9.990% | 3,415,314 (+1069.96%) | Filing History |
| 2024-02-14 4:51 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Nantahala Capital Management LLC | 0 0.000% | -184,452 (Position Closed) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | EcoR1 Capital LLC | 887,076 2.500% | 887,076 (New Position) | Filing History |
| 2024-02-14 4:27 pm Unchanged | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.200% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | BAKER BROS. ADVISORS LP | 0 0.000% | -255,361 (Position Closed) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Commodore Capital LP | 1,934,084 5.400% | 100,000 (+5.45%) | Filing History |
| 2024-02-14 3:51 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Logos Global Management LP | 150,000 0.400% | -104,000 (-40.94%) | Filing History |
| 2024-02-14 2:07 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Rock Springs Capital Management LP | 0 0.000% | -136,556 (Position Closed) | Filing History |
| 2024-02-14 09:08 am Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 2,125,597 5.900% | 2,125,597 (New Position) | Filing History |
| 2024-02-14 08:56 am Purchase | 2023-12-31 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Deep Track Capital, LP | 2,184,440 6.030% | 1,894,118 (+652.42%) | Filing History |
| 2024-02-14 07:02 am Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | RTW INVESTMENTS LP | 2,232,760 6.200% | 2,232,760 (New Position) | Filing History |
| 2024-02-13 6:46 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | BCLS II Equity Opportunities LP | 0 0.000% | -213,908 (Position Closed) | Filing History |
| 2024-02-13 5:28 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | SUVRETTA CAPITAL MANAGEMENT LLC | 412,395 1.000% | 157,340 (+61.69%) | Filing History |
| 2024-02-13 4:48 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Affinity Asset Advisors LLC | 653,409 1.810% | 354,329 (+118.47%) | Filing History |
| 2024-02-13 09:39 am Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Polar Capital Holdings Plc | 500,000 1.050% | 342,552 (+217.57%) | Filing History |
| 2024-02-12 12:03 pm Purchase | 2024-02-09 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 6,206,451 13.065% | 2,420,574 (+63.94%) | Filing History |
| 2024-02-09 10:20 am Purchase | 2024-02-08 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 3,785,877 7.969% | 3,785,877 (New Position) | Filing History |
| 2024-02-08 4:36 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | INTEGRATED CORE STRATEGIES (US) LLC | 108,486 0.300% | -16,773 (-13.39%) | Filing History |